Edition:
United Kingdom

ZIOPHARM Oncology Inc (ZIOP.OQ)

ZIOP.OQ on NASDAQ Stock Exchange Capital Market

2.13USD
8:29pm GMT
Change (% chg)

$-0.14 (-6.17%)
Prev Close
$2.27
Open
$2.28
Day's High
$2.30
Day's Low
$2.10
Volume
196,917
Avg. Vol
414,323
52-wk High
$5.24
52-wk Low
$1.56

Latest Key Developments (Source: Significant Developments)

Ziopharm Oncology And TriArm Therapeutics Establish Joint Venture To Develop And Commercialize Sleeping Beauty CAR T In China, Taiwan & Korea
Wednesday, 19 Dec 2018 

Dec 19 (Reuters) - ZIOPHARM Oncology Inc ::ZIOPHARM ONCOLOGY AND TRIARM THERAPEUTICS ESTABLISH JOINT VENTURE TO DEVELOP AND COMMERCIALIZE SLEEPING BEAUTY CAR T IN CHINA, TAIWAN AND KOREA.ZIOPHARM ONCOLOGY INC - TRIARM THERAPEUTICS, A PANACEA VENTURE HEALTHCARE COMPANY, TO FUND EDEN BIOCELL WITH UP TO $35M.ZIOPHARM ONCOLOGY INC - JOINT VENTURE TO OPERATE AS EDEN BIOCELL.ZIOPHARM ONCOLOGY INC - ZIOPHARM TO LICENSE RIGHTS OF THIRD-GENERATION SLEEPING BEAUTY CD19-SPECIFIC CAR-T CELL THERAPIES TO EDEN BIOCELL.ZIOPHARM ONCOLOGY INC - EDEN BIOCELL TO BE OWNED EQUALLY (50-50) BY ZIOPHARM AND TRIARM.ZIOPHARM ONCOLOGY INC - CEO LAURENCE COOPER, PANACEA VENTURE HEALTHCARE'S JAMES HUANG WILL SERVE ON EDEN BIOCELL'S BOARD.ZIOPHARM ONCOLOGY INC - TRIARM WILL MANAGE ALL CLINICAL DEVELOPMENT TO EXECUTE TRIALS IN CHINA FOR EDEN BIOCELL.ZIOPHARM ONCOLOGY INC - CEO LAURENCE COOPER, JAMES HUANG WILL SHARE DECISION-MAKING AUTHORITY FOR EDEN BIOCELL.  Full Article

Ziopharm Oncology Promotes David Mauney To President
Thursday, 13 Dec 2018 

Dec 13 (Reuters) - ZIOPHARM Oncology Inc ::ZIOPHARM ONCOLOGY PROMOTES DR. DAVID MAUNEY TO PRESIDENT.ZIOPHARM ONCOLOGY INC - DAVID MAUNEY, HAS BEEN PROMOTED TO PRESIDENT EFFECTIVE IMMEDIATELY.  Full Article

Ziopharm Oncology Announces Immuno-Oncology Clinical Supply Agreement With Regeneron
Monday, 12 Nov 2018 

Nov 12 (Reuters) - ZIOPHARM Oncology Inc ::ZIOPHARM ONCOLOGY ANNOUNCES IMMUNO-ONCOLOGY CLINICAL SUPPLY AGREEMENT WITH REGENERON TO EVALUATE COMBINATION THERAPY FOR PATIENTS WITH BRAIN CANCER.ZIOPHARM ONCOLOGY INC - UNDER AGREEMENT ZIOPHARM AND REGENERON WILL INITIATE A PHASE 2 STUDY IN FIRST HALF OF 2019 IN PATIENTS WITH RGBM.ZIOPHARM ONCOLOGY INC - PHASE 2 STUDY TO MEASURE PRELIMINARY SAFETY AND EFFICACY OF AD-RTS-HIL-12 PLUS VELEDIMEX IN COMBINATION WITH LIBTAYO.ZIOPHARM ONCOLOGY INC - UNDER AGREEMENT ZIOPHARM WILL BE RESPONSIBLE FOR CONDUCT AND COSTS OF CLINICAL TRIAL, AND REGENERON WILL SUPPLY LIBTAYO FOR STUDY.  Full Article

Ziopharm Oncology Q2 Loss Per Share $0.12
Wednesday, 8 Aug 2018 

ZIOPHARM Oncology Inc ::ZIOPHARM ONCOLOGY REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q2 LOSS PER SHARE $0.12.Q2 EARNINGS PER SHARE VIEW $-0.12 -- THOMSON REUTERS I/B/E/S.  Full Article

Ziopharm Oncology To Initiate Pivotal Trial Of Cancer Treatment in Second Half of 2018
Tuesday, 9 Jan 2018 

Jan 9 (Reuters) - Ziopharm Oncology Inc ::ZIOPHARM ONCOLOGY PROVIDES UPDATE ON STANDOUT TECHNOLOGIES DURING THE 36TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE.ZIOPHARM ONCOLOGY - UPDATED GUIDANCE ON PLANNED PIVOTAL TRIAL TO EVALUATE CONTROLLED IL-12 AND ANNOUNCED THAT IT WILL INITIATE IN SECOND HALF OF 2018.  Full Article

Ziopharm Oncology reports third quarter financial results
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Ziopharm Oncology Inc :Ziopharm Oncology reports third quarter 2017 financial results and provides update on recent activities.Q3 loss per share $0.13.Q3 earnings per share view $-0.14 -- Thomson Reuters I/B/E/S.  Full Article